Century Therapeutics (NASDAQ: IPSC) — Perfil da empresa, notícias e dados financeiros
Century Therapeutics specializes in cellular therapies for cancer treatment, leveraging iPSC technology for innovative, effective solutions.
Century Therapeutics
Century Therapeutics (NASDAQ:IPSC) is a biotechnology firm focused on developing innovative therapies to improve the outcomes of cancer patients. Specializing in cellular therapies, Century Therapeutics is pioneering the development of products with the potential to treat not only hematologic cancers but also solid tumors. The company's projects leverage cutting-edge iPSC (induced pluripotent stem cell) technology to manufacture cell therapies that are more effective, accessible, and easier to produce than traditional methods. With a commitment to revolutionizing cancer treatment, Century Therapeutics aims to advance its clinical programs and expand its pipeline to address a broad range of cancers, ultimately striving to bring novel, life-saving treatments to the market.
Resumo
Operações
Produtos e/ou serviços de Century Therapeutics
- iPSC-derived allogeneic cell therapies for cancer, utilizing engineered immune cells to target hematologic and solid tumors.
- Development of CNTY-101, an iPSC-derived NK cell product for treating acute myeloid leukemia.
- Advancement of CAR-iT cells targeting CD19 for B-cell malignancies, leveraging iPSC technology for scalable production.
- Research on engineered iPSC-derived macrophages (CAR-M) for potential treatment of solid tumors, focusing on enhanced phagocytosis.
- Collaboration on iPSC-derived T cell therapies for various cancer targets, emphasizing off-the-shelf availability and reduced risk of graft-versus-host disease.
- Investment in proprietary engineering platforms to enhance the efficacy, safety, and manufacturability of cell therapy products.
equipe executiva do Century Therapeutics
- Brent PfeiffenbergerPresident, CEO & Chairman
- Gregory RussottiChief Technology & Manufacturing Officer
- Chad A. CowanChief Scientific Officer
- Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary
- Krista KauppinenVP, General Counsel & Head of Intellectual Property
- Megan BilsonChief People Officer
- Michael NasoSenior VP of Cell Engineering
- Elizabeth DevlinVP & Head of Development
Principais indicadores financeiros
Resultados divulgados pela Century Therapeutics, em USD.
- Cap. de mercado
- 262,6 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 109,2 mi | -15 mi | -9,6 mi | |
| 6,6 mi | -138,1 mi | -126,6 mi | |
| 2,2 mi | -146,5 mi | -136,7 mi | |
| 5,2 mi | -133,8 mi | -130,9 mi |